A randomised, parallel group trial comparing two stepwise treatment tracks for the pharmacological management of adult asthma: ICS/formoterol reliever vs SABA reliever-based therapy

Start Date11 Apr 2025

Sponsor / Collaborator

Medical Research Institute of New Zealand

NCT06865040

/ Not yet recruitingNot Applicable

Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

Start Date04 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire Amiens-Picardie

CTRI/2024/10/075606

/ RecruitingPhase 3

A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL

Start Date07 Nov 2024

Sponsor / Collaborator

Glenmark Pharmaceuticals Ltd.

100 Clinical Results associated with Formoterol Fumarate

100 Translational Medicine associated with Formoterol Fumarate

100 Patents (Medical) associated with Formoterol Fumarate

3,144

Literatures (Medical) associated with Formoterol Fumarate

31 Dec 2025·Pulmonology

Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Article

Author: Bedbrook, A. ; Makela, M. ; Samolinski, B. ; Rivero Yeverino, D. ; Klimek, L. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Ivancevich, J.C. ; Buhl, R. ; Kraxner, H. ; Anto, J.M. ; Pétré, B. ; Haahtela, T. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Sousa-Pinto, B. ; Brussino, L. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Valiulis, A. ; Niedoszytko, M. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Bosnic-Anticevich, S. ; Suppli Ulrik, C. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.

INTRODUCTION:

Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.

MATERIALS AND METHODS:

We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.

RESULTS:

In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).

CONCLUSIONS:

In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation

Article

Author: Yu, Shule ; Wang, Menglei ; Yang, Qingqing ; Lu, Wei ; Guo, Wei ; Zheng, Fangfang ; Chen, Hongdou ; Wu, Huanhuan ; Li, Wei

Background:

The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.

Methods:

Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.

Results:

The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.

Conclusions:

The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.

01 Nov 2025·NEUROCHEMISTRY INTERNATIONAL

Activation of the β2-adrenoceptor by formoterol induces calcium-dependent exocytosis of synaptic vesicles at the neuromuscular junction in a sex-specific manner

Article

Author: Guatimosim, Cristina ; Pereira, Elisa Santiago ; Santos, Kivia B S ; Cavalcante, Walter ; de Castro Fonseca, Matheus ; Birbrair, Alexander ; Tapia, Juan C ; Verly, Pablo W ; Teixeira, Gabriel H M ; Sanches, Bruno ; Rossi, Leonardo ; Bloise, Enrrico ; Guatimosim, Silvia

Increasing evidence suggests that the sympathetic nervous system profoundly interacts with skeletal muscle, influencing both muscle fiber function and composition. β₂-ARs, the predominant adrenergic receptor subtype in muscle fibers, have been shown to enhance protein synthesis, reduce protein degradation, facilitate muscle contraction and relaxation, and improve neuromuscular junction (NMJ) transmission upon activation. In this study, we investigated the effects of Formoterol, a highly selective β₂-adrenoceptors (β₂-AR) agonist, on the presynaptic terminal of motor neurons. We used myography, FM1-43 fluorescent dye assays, and transmission electron microscopy (TEM) to evaluate the NMJ following β₂-AR activation. We demonstrated that β₂-AR activation by Formoterol enhances muscle contractility and both spontaneous and evoked exocytosis of acetylcholine (ACh)-containing synaptic vesicles at the mouse diaphragm NMJ. Formoterol-induced morphological changes in diaphragmatic NMJs were consistent with increased exo-endocytic activity. Notably, Formoterol-evoked exocytosis displayed sexual dimorphism, with females showing a significantly milder response compared to males. In females, Formoterol-induced synaptic vesicles exocytosis was mediated solely by P/Q-type voltage-activated Ca²⁺ channels, whereas in males, it involved both P/Q-type channels, transient receptor potential channel of the vanilloid subtype (TRPV) 1 calcium channels, and an additional, yet unidentified, component. Orchiectomized males exhibited responses to Formoterol similar to the females, whereas ovariectomy did not modify female drug responses, indicating that male hormonal environment orchestrates the sex-differences herein described. These findings not only highlight the importance of sex-specific mechanisms but also reveal a novel effect of β₂-AR activation directly on presynaptic terminals by Formoterol, enhancing exocytosis at the NMJ and thereby increasing neuromuscular transmission.

News (Medical) associated with Formoterol Fumarate

25 Jul 2025

·www.astrazeneca.com

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, endorsing it for use in the European Union (EU) with an innovative, next-generation propellant with near-zero Global Warming Potential (GWP).1 Trixeo is the first medicine delivered by a pressurised metered-dose inhaler (pMDI) using a propellant that offers 99.9% lower GWP than propellants used in currently available pMDIs.2 This fixed-dose triple-combination therapy, marketed as Breztri Aerosphere in the US, China and Japan, will now have a low carbon footprint comparable to inhaled medicines that do not require a propellant.3 Based on the CHMP positive opinion, AstraZeneca will now begin to transition its Trixeo supply to the next-generation propellant in Europe. The CHMP positive opinion is based on results from the next-generation propellant clinical development programme, which demonstrated bioequivalence between Trixeo with the next-generation propellant and Trixeo with the current propellant.4,5 The safety and tolerability profile for Trixeo with the next-generation propellant was consistent with the known profile of the medicine. Frederik Trinkmann, Professor and Senior Pulmonologist at the Thoracic Clinic at Heidelberg University Hospital, Germany, said: “Respiratory medicines delivered by pressurised metered-dose inhalers are essential for millions of people living with respiratory diseases in Europe, including specific vulnerable populations such as children and the elderly. The transition of Trixeo to the propellant with near-zero Global Warming Potential ensures clinicians’ treatment decisions can focus on clinical needs while also supporting environmental goals.” Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “The CHMP positive opinion of Trixeo Aerosphere with the next-generation propellant allows us to address the needs of both patients and the planet and is a significant milestone in our commitment to delivering innovations for sustainable healthcare in the EU. Starting with Trixeo, the transition to the near-zero Global Warming Potential propellant across our pressurised metered-dose inhaled respiratory medicines is an important step towards achieving our Ambition Zero Carbon strategy.” Susanna Palkonen, Director of the European Federation of Allergy and Airways Diseases Patients' Associations, said: “COPD is a devastating disease and the third leading cause of mortality in the world. People living with COPD need access to a treatment which is right for them as well as a healthy environment and clean air. We welcome the positive opinion from the CHMP for the inhaled respiratory medicine containing the next-generation propellant with a significantly reduced carbon footprint.” Trixeo with the next-generation propellant received its first approval in the UK in May 2025 with regulatory applications also currently under review in China and additional countries. Trixeo is the first medicine in AstraZeneca’s portfolio of medicines delivered by pMDIs to transition to the new propellant. AstraZeneca aims to transition its wider pMDI portfolio to the near-zero GWP propellant by 2030 as part of the Company’s Ambition Zero Carbon strategy. In the EU, the Company plans to initiate the transition of Trixeo to the next-generation propellant in the coming months. Chronic respiratory diseases, including COPD, affect hundreds of millions of people around the world.6 Respiratory inhaled medicines delivered by pMDIs account for 76% of all inhaler use in Europe, and contribute 0.04% of global greenhouse gases.7,8 Studies show that the largest environmental contribution from respiratory diseases comes from patients’ symptoms not being adequately controlled and resulting increased healthcare utilisation.9,10 Implementing evidence-based guidelines into clinical practice can reduce exacerbations and unscheduled healthcare utilisation, and the resulting improved patient outcomes may also decrease the overall carbon footprint associated with respiratory care.11 Notes AstraZeneca’s next-generation propellant clinical development programme The clinical development programme has been initiated to assess the efficacy and safety of the next-generation, near-zero Global Warming Potential propellant with the AstraZeneca portfolio of inhaled medicines delivered by pressurised metered-dose inhalers (pMDIs). The first medicine to be assessed in the programme was Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) through in vitro, in vivo bioequivalence (PK), safety and efficacy clinical studies.12-17 The programme established bioequivalence between Breztri/Trixeo with the next-generation propellant and Breztri/Trixeo with the current propellant.4,5 The safety and tolerability profile for Breztri/Trixeo with the next-generation propellant was consistent with the known profile of the medicine. Additional studies are underway to assess the bioequivalence of the next-generation propellant to the current propellant with AstraZeneca’s other medicines delivered by pMDIs. Breztri/Trixeo Aerosphere Budesonide/glycopyrronium/formoterol fumarate (BGF), approved under the brand name Trixeo Aerosphere in the EU and UK and Breztri Aerosphere in Japan, China and the US, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a long-acting β2 agonist (LABA), glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an inhaled corticosteroid (ICS), and delivered via the Aerosphere pMDI. Breztri/Trixeo Aerosphere is approved to treat COPD in more than 80 countries worldwide including the US, EU, China, Japan, and has been prescribed to more than five million patients globally. Breztri/Trixeo Aerosphere with the next-generation propellant will maintain the same indication, product strength and dosage regimen as Breztri/Trixeo Aerosphere with the current propellant. AstraZeneca’s Collaboration with Honeywell Developed by Honeywell, the medical grade version of the next-generation propellant is critical to enable the transition of pMDI medicines with reduced climate impact, given its near-zero GWP. AstraZeneca announced in 2022 its collaboration with Honeywell to develop respiratory inhaled medicines using the new propellant. Ambition Zero Carbon Through its Ambition Zero Carbon strategy, AstraZeneca is pursuing bold, science-based decarbonisation targets, accelerating progress towards net zero. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. AstraZeneca in Respiratory & Immunology Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company. AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References Corporate and financial

Drug Approval

10 Jul 2025

·endpoints.news

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

In a historic first, the FDA on Thursday released about 200 novel and generic drug rejection letters, bucking the agency’s former reticence to publicize the documents in one place. But it’s a small step as nearly all the letters reviewed by Endpoints News were previously disclosed as part of the drugs’ approval packages. Two of the complete response letters not previously disclosed included one for AstraZeneca’s COPD treatment Breztri Aerosphere in 2019 and one for a label update for Astellas’ eye drug Izervay in 2024. All of the rejection letters released are for drugs that have since been approved. AstraZeneca disclosed its CRL in a press release but did not mention that the FDA said the submitted data “do not provide substantial evidence of the efficacy and safety for the use of Breztri Aerosphere.” The CRL also said “the single Aerosphere phase 3 pivotal trial failed on the co-primary endpoint of change from baseline in trough FEV1 for the comparison of Breztri Aerosphere and the glycopyrrolate and formoterol fumarate combination.” AstraZeneca said in a statement to Endpoints that its 2019 press release on the Breztri complete response letter “is an accurate reflection of the status of the regulatory filing and data at the time.” Breztri was later approved in 2020 following submission of additional data. For Izervay’s label expansion, Astellas also announced the CRL in a press release in 2024, but said the FDA comments outlined in the CRL “focus on a statistical matter” and “are unrelated to the safety and benefit/risk of the use of IZERVAY.” The FDA, however, said in the CRL that the company’s proposal to extend the dosing interval “was not supported by the submitted data and was not replicated in a second adequate and well controlled study.” Astellas did not immediately respond to a request for comment. The FDA noted that according to a 2015 analysis conducted by FDA researchers, drug companies “avoided mentioning 85% of the FDA’s concerns about safety and efficacy when announcing publicly that their application was not approved. Moreover, when FDA calls for a new clinical trial for safety or efficacy, that critical information is not disclosed approximately 40% of the time.” The FDA said the CRLs have been redacted for trade secrets and confidential commercial information. It’s unclear if the agency contacted the sponsors prior to releasing the new letters. The agency also said it is in the process of publishing additional CRLs from its archives. “For far too long, drug developers have been playing a guessing game when navigating the FDA,” FDA Commissioner Marty Makary said in a statement. “Drug developers and capital markets alike want predictability. So today we’re one step closer to delivering it to them, with an ultimate goal of bringing cures and meaningful treatments to patients faster.” Editor’s Note: This story was updated with comment from AstraZeneca. An earlier version was updated to reflect a review of the documents released today, finding that some were previously disclosed in approval packages.

Phase 3Drug Approval

13 May 2025

·www.pharmaceutical-technology.com

MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD

AstraZeneca plans to transition its pMDI portfolio to the near-zero GWP propellant by 2030. Credit: Elzbieta Krzysztof / Shutterstock. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) inhaler for use with a propellant with near-zero Global Warming Potential (GWP), to treat adults with chronic obstructive pulmonary disease (COPD). This step marks the first time a medicine delivered by a pressurised metered-dose inhaler (pMDI) utilises a propellant with a 99.9% lower GWP compared to currently used propellants. The approval was based on the propellant clinical development programme outcomes, which confirmed bioequivalence between Trixeo with the new propellant, HFO-1234ze(E), and the existing propellant, HFA-134a. Trixeo’s tolerability and safety profile were found to be consistent with its known characteristics. Trixeo, known as Breztri Aerosphere in the US, China, and Japan, is a fixed-dose triple-combination therapy for COPD. The therapy combines a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and an inhaled corticosteroid (ICS), delivered through the Aerosphere pMDI. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence AstraZeneca plans to transition its pMDI portfolio to the near-zero GWP propellant by 2030, aligning with its Ambition Zero Carbon strategy. The transition of Trixeo Aerosphere in the UK is set to begin in the coming months. Regulatory applications for Trixeo/Breztri Aerosphere with the next-generation propellant are also under review in China, Europe, and other nations. AstraZeneca biopharmaceuticals business unit executive vice-president Ruud Dobber said: “The UK approval of Trixeo Aerosphere with the next-generation propellant is an industry first and a major milestone in AstraZeneca’s commitment to transition our pMDI portfolio to the propellant with near-zero GWP. “Starting with Trixeo, we are addressing the needs of both patients and the environment in devastating diseases like COPD, which affects hundreds of millions of people and is a leading cause of death globally.” Honeywell-developed medical-grade HFO-1234ze(E) is pivotal for decreasing the climate impact of pMDI medicines. In 2022, AstraZeneca announced a partnership with Honeywell to develop respiratory inhaled medicines with the new propellant. As part of its Ambition Zero Carbon strategy, AstraZeneca is progressing towards net zero emissions, targeting a 98% reduction in greenhouse gas emissions from its operations by 2026, from a 2015 baseline.

Drug Approval

100 Deals associated with Formoterol Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D01373	Formoterol Fumarate	R03AC13	DBSALT001371

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	China	Ningbo Team Pharm Co. Ltd.	26 Nov 2008
Asthma	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Asthma, Exercise-Induced	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Bronchial Spasm	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Bronchitis, Chronic	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Lung Diseases, Obstructive	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Pulmonary Disease, Chronic Obstructive	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001
Pulmonary Emphysema	United States	Novartis Pharmaceuticals Corp.	16 Feb 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
airway disease	Phase 3	Sweden	AstraZeneca PLC	01 Oct 2004
Persistent asthma	Phase 2	Germany	Novartis AG	01 Feb 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01787097 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive	31	Symbicort® total dose 400ug/12ug (Symbicort® Total Dose 400ug/12ug)	lqvgvroash(irluiixtsl) = uncnewnzsw ifkbdurlqe (lxjblpmfgx, 0.1) View more	-	23 Nov 2020
				Symbicort® total dose 800ug/24ug (Symbicort® Total Dose 800ug/24ug)	lqvgvroash(irluiixtsl) = htjabowkzw ifkbdurlqe (lxjblpmfgx, 0.4) View more
NCT03028701 (Pubmed \| Clin Drug Investig)	Phase 4	Pulmonary Disease, Chronic Obstructive	33	Single-Dose 12/400-µg Formoterol/Budesonide Combination	tigfpcziww(qtzaufrtto) = lxtkcnasub uyxnuwenbp (qyntjcmkff )	-	01 Oct 2019
NCT00159263 (CTgov)	Not Applicable	Asthma	10	Placebos (Placebo)	yolcgwbgvt(uesxtmgiwe) = kwbksjnfwd miomxuccdo (ighffjijjz, himaysnjyr - purzozmvoq) View more	-	27 Sep 2019
				Formoterol Inhalant Powder (Formoterol)	yolcgwbgvt(uesxtmgiwe) = csldawzvox miomxuccdo (ighffjijjz, gnzcqzlsmh - pizxejzdoa) View more
NCT02727660 (SOPHOS, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	1,876	Budesonide Formoterol Fumarate (BFF MDI 320/9.6 ug)	wfwlcxaqbz(ohugyiquhw) = xsxiblsexk fatfnqfqqa (rmluxxvbth, uuwwjclfzx - mkgvtqaghv) View more	-	26 Sep 2019
				BFF (BFF MDI 160/9.6 ug)	wfwlcxaqbz(ohugyiquhw) = kxwlllrpjh fatfnqfqqa (rmluxxvbth, wkxgeecyoo - bablhyopig) View more
NCT01912872 (MEXIC, CTgov)	Phase 4	Severe asthma	112	Budesonide+Formoterol+Omalizumab (Pediatric Patients: Omalizumab + Budesonide and Formoterol)	iaeusbfpap(lsfqwhbwbw) = haezaahncq euqkntgnpi (mcjgxdbblf, 95.74) View more	-	02 Jul 2019
				Budesonide+Formoterol (Pediatric Patients: Budesonide and Formoterol)	iaeusbfpap(lsfqwhbwbw) = djzdhbsbbu euqkntgnpi (mcjgxdbblf, 98.52) View more
NCT02343458 (CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	1,756	Placebo MDI	itlqbudzkx(iijtbhftro) = mqrqblnqyx xkkpmperjg (frproqhpia, htilmfjyxe - hmozwpbvka) View more	-	20 Feb 2019
NCT02796677 (AMPLIFY \| D6571C00001, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	1,595	AB (AB/FF 400/12 μg)	hgapbmfwwp(vsirkujnkv) = arzlltitms vfnllzrkle (kmxplbaxwt, 0.013) View more	-	09 Nov 2018
				AB (AB 400 μg)	hgapbmfwwp(vsirkujnkv) = tfdbccrtef vfnllzrkle (kmxplbaxwt, 0.011) View more
NCT02796651 (CTgov)	Phase 2	Pulmonary Disease, Chronic Obstructive \| airway disease	132	Formoterol Fumarate (Formoterol Fumarate 6 μg)	kigdkfojew(snbdjnmylv) = xdjjvoxlhl eecilnmpvd (qptdiofhld, xqkksowmch - awctrztkzn) View more	-	07 Feb 2018
				Formoterol Fumarate (FF) (Formoterol Fumarate (FF) 12 μg)	kigdkfojew(snbdjnmylv) = kvfmtngjyw eecilnmpvd (qptdiofhld, lkjgffabkx - kjqxbjlrmr) View more
NCT01488019 (CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive	1,071	Perforomist (Perforomist Inhalation Solution)	kyltkfdzar = vioesjrfzg hbaytigtkd (nphxkhnzbg, oqqsuvzfae - hetmpedsow) View more	-	12 Jun 2017
				placebo (Matching Placebo)	kyltkfdzar = rrixzoqadi hbaytigtkd (nphxkhnzbg, bnilhqtpuh - pjhoujzxqs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis